The manufacturer of a breast cancer drug which has been deemed "too expensive" to be offered by the NHS has hit back at the decision.
Dr Jayson Dallas, general manager of Roche Products Limited, declared it "an incredible injustice."
Despite Roche offering a significant discount, we are once again disappointed that Nice has not shown any flexibility on access to Kadcyla.
Refusing patients access to this drug is an incredible injustice and tantamount to turning the clock back in cancer research and development. We plan to appeal this decision.
More top news
Malaysia has recalled its ambassador to North Korea as tensions over the investigation into the death of Kim Jong-nam boiled over.
The NHS is at "breaking point" with declining numbers of beds compounding the situation, according to the British Medical Association.
Donald Trump's ambiguous phrase "what's happening in Sweden" during a rally on Saturday was a reference to a Fox News story, he has claimed.